Generate Biomedicines Inc. (GENB) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Generate Biomedicines Inc. (NASDAQ: GENB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.46 (-8.31% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZYME (Zymeworks Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).
Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 57/100 (D+) score, GENB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.99) or 200D SMA ($14.08) invalidates the momentum regime and cuts Target Base ($14.39) toward Bear Floor ($11.22).
Generate Biomedicines Inc. (GENB) dropped -8.31% to $14.46, trading at 30% of its 52-week range ($11 – $22.67). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Anthropic outlined collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences.
SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor
The tie-up marks the latest pharma company to enlist the AI-powered drug discovery services of Generate.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GENB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GENB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Generate Biomedicines Inc. (GENB) ranks #209 by composite RQD confidence (57/100, grade D+) and #262 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, GENB leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GENB
ACTIVE
Generate Biomedicines Inc. | D+ | 57/100 | — | — | — | -8.31% | $2.02B | Benchmark Subject |
| ZYME Zymeworks Inc. | D | 49/100 | — | — | -32.2% | -0.35% | $2.02B | /zyme-vs-genb → |
| SRPT Sarepta Therapeutics Inc. | D- | 35/100 | — | 96.0% | -35.0% | -3.17% | $2.03B | /srpt-vs-genb → |
| SLS SELLAS Life Sciences Group Inc. | D- | 39/100 | — | — | -21.8% | -4.68% | $2.05B | /sls-vs-genb → |
| TRVI Trevi Therapeutics Inc. | E | 30/100 | — | — | -23.7% | -1.81% | $1.97B | /trvi-vs-genb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, GENB closed FY2025 with $330.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $330.2M | — |
As of 2026-11-02, Generate Biomedicines Inc. (NASDAQ: GENB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.46 (-8.31% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZYME (Zymeworks Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).
Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
GENB last traded at $14.46 (-8.31% on volume of 1,170,878 shares), positioning the stock -3.54% below its 50-day simple moving average ($14.99) and +2.70% above its 200-day simple moving average ($14.08). Across its 52-week range of $11.00 to $22.67, GENB sits at the 29.6% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($12.65 to $16.27).
Why GENB Stock dropped -8.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, GENB scores 57 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
Taken together, the investor implication is that the rating's upside case depends on institutional and balance-sheet support rather than on current cash generation, which the source data shows at zero. Valuation tradeoffs are significant: with ROIC and FCF yield both at 0%, any upside thesis must rest on future growth not evidenced in the current financial data. The rating's "Trim" verdict signals that the framework views current risk-reward as unfavorable.
Generate Biomedicines Inc. (GENB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue for FY 2025 is $0.0M, and the source data does not identify how the company generates income.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | $121.7M | N/A |
Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $121.7M. Per market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. The source data does not provide a debt figure in dollars, so the debt level cannot be independently verified beyond the ratio.
Per the recent news feed, five items reference GENB:
Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND with a macro tailwind score of 18/100, severity 94, direction BEARISH. The signal states GENB exhibits a 3.73x True Net Liquidity elasticity with r = +0.21, and that the Net Liquidity Index stands at $5,745.73B with a -0.64% 4-week rate of change and High-Yield OAS at +2 bps. Risk watch: the bearish liquidity signal is the dominant proprietary flag, and the milestone-linked figure is a contingent, not a booked, revenue source.
Per the Butterfly Supply-Chain Graph, supply_chain is NONE and no butterfly links are listed, so upstream and downstream dependencies are not available in source data. The only sector-level linkage is the liquidity signal above: a 3.73x beta to Net Liquidity means GENB's price is expected to be highly sensitive to shifts in Fed balance-sheet, Treasury General Account, and reverse-repo flows. A second-order watch item is that a tightening in these liquidity inputs would, per the signal's own framing, pressure the stock disproportionately relative to a 1.0 market beta. The contingent AI-obesity milestone structure noted in the news feed would represent a future ripple into the company's own financials, but the source data does not quantify timing or probability.
Real-time company headlines, analyst actions, and sector developments for Generate Biomedicines Inc. (GENB) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Generate Biomedicines Inc. (GENB) market action, institutional positioning, and fundamental catalysts.
Anthropic outlined collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences.
Welcome to the GENB (Generate Biomedicines Inc.) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on GENB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Generate Biomedicines Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on GENB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.77 (52-wk range $11.00 - $22.67), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).